BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31161695)

  • 1. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer.
    Cheng Y; Nie L; Liu Y; Jin Z; Wang X; Hu Z
    Thorac Cancer; 2019 Jul; 10(7):1576-1580. PubMed ID: 31161695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
    BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
    Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
    Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
    Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
    Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
    Li N; Jin ZL; Liu ZJ; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
    Yang H; Sui Y; Guo X; Tan X; Li Y; Wang M
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1148-S1151. PubMed ID: 30539861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study.
    Yao D; Shen H; Huang J; Yuan Y; Dai H
    Medicine (Baltimore); 2018 Aug; 97(32):e11822. PubMed ID: 30095656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
    Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
    J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
    Zhang FL; Gao EY; Shu RB; Wang H; Zhang Y; Sun P; Li M; Tang W; Jiang BQ; Chen SQ; Cui FB
    Asian Pac J Cancer Prev; 2015; 16(15):6765-8. PubMed ID: 26434908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
    Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
    Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
    Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
    Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
    Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
    Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
    Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
    Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
    Rong B; Yang S; Li W; Zhang W; Ming Z
    World J Surg Oncol; 2012 Aug; 10():170. PubMed ID: 22917490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
    Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
    Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
    An J; Lv W
    Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
    Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
    Asian Pac J Cancer Prev; 2011; 12(11):2901-7. PubMed ID: 22393961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.